{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:55:32Z","timestamp":1794246932312,"version":"4.9.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations in Rheumatology","award":["QoC015"],"award-info":[{"award-number":["QoC015"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ard-2023-224762","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T13:20:16Z","timestamp":1697116816000},"page":"15-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1089,"title":["EULAR recommendations for the management of systemic lupus erythematosus: 2023 update"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-031X","authenticated-orcid":false,"given":"Antonis","family":"Fanouriakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-7475","authenticated-orcid":false,"given":"Myrto","family":"Kostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1093","authenticated-orcid":false,"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Boletis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-1585","authenticated-orcid":false,"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-083X","authenticated-orcid":false,"given":"Frederic A","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-3570","authenticated-orcid":false,"given":"Lu\u00eds Sousa","family":"In\u00eas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Kouloumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-1228","authenticated-orcid":false,"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-7837","authenticated-orcid":false,"given":"Johanna","family":"Mucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-6667","authenticated-orcid":false,"given":"Chetan B","family":"Mukhtyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Pego-Reigosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5373","authenticated-orcid":false,"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A","family":"Pons-Estel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-3244","authenticated-orcid":false,"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"YK Onno","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-9333","authenticated-orcid":false,"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward M","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-8311","authenticated-orcid":false,"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224762_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. report of a task force of the EULAR standing committee for International clinical studies including therapeutics","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib2","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/annrheumdis-2021-221270","article-title":"From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift","volume":"81","author":"Parodis","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/annrheumdis-2021-221817","article-title":"Treatment of lupus: more options after a long wait","volume":"81","author":"Kostopoulou","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib11","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1136\/ard-2023-224762_bib12","unstructured":"Holwick J, Chalmers I, Galsziou P, et al. Explanation of the 2011 Oxford centre for evidence-based medicine (OCEBM) levels of evidence (background document). In: Oxford Centre for Evidence-Based Medicine. 2011."},{"key":"10.1136\/ard-2023-224762_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001263","article-title":"Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations","volume":"6","author":"Kostopoulou","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224762_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-224762_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of Belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmunity Reviews"},{"key":"10.1136\/ard-2023-224762_bib16","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","author":"Parodis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/Ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib19","first-page":"74","article-title":"From first symptoms to diagnosis of systemic lupus erythematosus: mapping the journey of patients in an observational study","volume":"41","author":"Kapsala","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0961203320983445","article-title":"Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the lula cohort","volume":"30","author":"Kernder","year":"2021","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224762_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224762_bib22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.berh.2013.07.001","article-title":"Adherence to treatment in systemic lupus erythematosus patients","volume":"27","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1136\/ard-2023-224762_bib25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-224762_bib26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/acr.24155","article-title":"Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta\u2010analysis","volume":"73","author":"Garg","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib27","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1136\/ard-2023-224762_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the lupus-cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/acr.24541","article-title":"Predictors of osteonecrosis in systemic lupus erythematosus: a prospective cohort study","volume":"74","author":"Kallas","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/acr.24592","article-title":"Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score-matched analysis","volume":"74","author":"Tselios","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2015.05.011","article-title":"Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis","volume":"14","author":"Ruiz-Arruza","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib33","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224762_bib35","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2023-224762_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224762_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"J\u00f3nsd\u00f3ttir","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib39","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/kep124","article-title":"Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis","volume":"48","author":"Li","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-224762_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of Rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2017.03.008","article-title":"Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"16","author":"Leone","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib44","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2023-224762_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2017.08.045","article-title":"Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-224762_bib46","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1177\/0961203318768877","article-title":"Combined mepacrine\u2013hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity","volume":"27","author":"Ugarte","year":"2018","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224762_bib47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-224762_bib48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2021.09.017","article-title":"Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study","volume":"87","author":"Keyes","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-224762_bib49","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib50","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in cutaneous lupus erythematosus after twenty weeks of Belimumab use: a systematic review and meta\u2010analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-224762_bib52","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jaad.2020.11.014","article-title":"Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: a multicenter retrospective observational study of 40 patients","volume":"84","author":"Aitmehdi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-224762_bib53","doi-asserted-by":"crossref","first-page":"v52","DOI":"10.1093\/rheumatology\/keaa404","article-title":"The management of neuropsychiatric lupus in the 21st century: still so many unmet needs","volume":"59","author":"Govoni","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib54","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/rheumatology\/keu384","article-title":"Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus","volume":"54","author":"Bortoluzzi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib55","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3899\/jrheum.081133","article-title":"Prospective study of neuropsychiatric events in systemic lupus erythematosus","volume":"36","author":"Hanly","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence","volume":"41","author":"Narv\u00e1ez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224762_bib57","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1136\/ard-2023-224762_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/09612033221144425","article-title":"Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: a real-life single-center study","volume":"32","author":"Moysidou","year":"2023","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224762_bib59","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224762_bib60","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/rheumatology\/keab925","article-title":"Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients","volume":"61","author":"Roussotte","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.medcli.2015.03.014","article-title":"Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Catal\u00e1-L\u00f3pez","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1136\/ard-2023-224762_bib62","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224762_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2023-224762_bib64","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224762_bib65","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224762_bib66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-224762_bib67","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2023-224762_bib68","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1093\/rheumatology\/keab126","article-title":"Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study","volume":"60","author":"Lu\u00eds","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1136\/ard-2023-224762_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.18433\/jpps30526","article-title":"Multitarget therapy: an effective and safe therapeutic regimen for lupus nephritis","volume":"22","author":"Zhou","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"10.1136\/ard-2023-224762_bib71","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"Update of the joint European league against rheumatism and European renal association\u2013European dialysis and transplant association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/keac221","article-title":"Challenging wisely: how to move beyond \u20181 mg\/kg then taper","volume":"62","author":"Tai","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib74","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2018-214559","article-title":"Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study","volume":"78","author":"Sciascia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1136\/ard-2023-224762_bib76","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib77","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib78","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224762_bib79","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib80","article-title":"Safety and efficacy of long\u2010term Voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","author":"Saxena","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib81","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study","volume":"61","author":"Walsh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2023-224762_bib82","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","article-title":"Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual","volume":"60","author":"Ji","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224762_bib83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib84","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr2.11267","article-title":"Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus","volume":"3","author":"Tselios","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib85","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224762_bib86","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-224762_bib87","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-224762_bib89","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy\u2013based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"10.1136\/ard-2023-224762_bib90","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/acr.24255","article-title":"Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population","volume":"73","author":"Jorge","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152046","article-title":"Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus","volume":"55","author":"Papachristos","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224762_bib92","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the systemic lupus international collaborating clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib93","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.24548","article-title":"Predictors of unsuccessful hydroxychloroquine tapering and discontinuation: can we personalize decision\u2010making in systemic lupus erythematosus treatment","volume":"74","author":"Almeida-Brasil","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000603","article-title":"Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis","volume":"9","author":"Ji","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224762_bib95","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1136\/ard-2023-224762_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224762_bib99","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201c;CAPS registry\u201d;","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224762_bib101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib102","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000574","article-title":"Herpes zoster in SLE: prevalence, incidence and risk factors","volume":"9","author":"Kwan","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224762_bib104","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-215925","article-title":"Safety and immune response of a live-attenuated herpes Zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial","volume":"78","author":"Mok","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune\u2010mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib106","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/rheumatology\/keac604","article-title":"COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance","volume":"62","author":"Tan","year":"2023","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-224762_bib107","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib108","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/annrheumdis-2019-216764","article-title":"Impact of the new American college of cardiology\/American heart association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus","volume":"79","author":"Tselios","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib109","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2022-222167","article-title":"Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis","volume":"81","author":"Hakroush","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224762_bib111","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real\u2010life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224762_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on Belimumab treatment: a real-life, multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2023","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224762_bib113","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2217\/cer-2022-0040","article-title":"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus","volume":"11","author":"Bruce","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1136\/ard-2023-224762_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000907","article-title":"Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks","volume":"10","author":"Neupane","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224762_bib115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib116","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib117","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/acr.23794","article-title":"A novel system to categorize the symptoms of systemic lupus erythematosus","volume":"71","author":"Pisetsky","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224762_bib118","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2017-212662","article-title":"EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis","volume":"77","author":"Geenen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib119","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/annrheumdis-2021-220438","article-title":"Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients","volume":"80","author":"Chavatza","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224762_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.12.019","article-title":"Impact of adherence to EULAR quality indicators on the quality of life of patients with systemic lupus erythematosus","volume":"109","author":"Taheri","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T09:09:06Z","timestamp":1749719346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0003496724003868"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224762","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ard-2023-224762.supp2","asserted-by":"subject"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}